

New updates to prior authorizations and post-service claim edits coming in 2024

Security Health Plan requires prior authorization (PA) and post-service claim edits (PSCE) on medications to ensure coverage and payment for those services. New requirements have been added for 2024 as we work to make sure all care, services and treatments are medically necessary.

Magellan will implement additional PA's and PSCE's Jan. 1, 2024, for the following drugs given in office and outpatient settings:

- Daxxify[®] (daxibotulinumtoxinA)
- Elrexfio[®] (elranatamab-bcmm)
- Izervay[®] (avacincaptad pegol)
- Talvey[®] (talquetamab-tgvs)
- Veopoz[®] (pozelimab-bbfg)
- Tyruko[®] (natalizumab-sztn)
- Eylea HD[®] (aflibercept)
- Aphexda[®] (motixafortide)
- Rivfloza[®] (nedosiran)
- Tofidence[®] (tocilizumab-bavi)
- Pombiliti[®] (cipaglucoasidase alfa-atga)
- Cosentyx IV[®] (secukinumab)
- Focinvez[®] (fosaprepitant)- Will be added to PSCE only when the drug receives a dedicated classified code (anticipated 1-1-24)

This is only the list of new prior authorizations and post-service claim edits required of members and providers to ensure payment for services. You can review the full list of all medications that will require a prior authorization and/or post-service claim edit on our website at www.securityhealth.org/providers/medical-pharmacy. If you have any questions, please contact Security Health Plan Provider Relations at 1-800-548-1224.